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Induced abortion is the termination of pregnancy by medical or surgical methods before the fetus’ 
viability. Available evidences show that due to spasmolytic effects, use of Hyoscine with Misoprostol 
may reduce the pain during abortion induction. The aim of this study is to evaluate the effect of 
Misoprostol in combination with Hyoscine compared with Misoprostol alone in reducing the duration of 
abortion induction. In a clinical trial at the Department of Obstetrics and Gynecology, Qazvin University 
of Medical Sciences on 126 pregnant women with gestational age below 20 weeks elected for abortion, 
the effect of Misoprostol in combination with Hyoscine compared with Misoprostol alone was evaluated 
in reducing the duration of abortion induction. The mean duration of abortion induction in Misoprostol 
with Hyoscine represented statistically significant decrease compared with Misoprostol (653.38 ± 80.386 
min, with 726.29 ± 64.56 min) (P ≤ 0.001). There was no significant difference in demographic 
characteristics, including maternal age, gestational age, gravidity, parity and history of abortion 
between the two study groups, and the two groups were homogeneous. Duration of abortion induction 
(p < 0.001), the rate of vaginal bleeding (p < 0.001), and the rate of hemoglobin deficiency (p = 0.002) in 
the group receiving Misoprostol suppositories and Hyoscine was significantly lower than in the group 
receiving Misoprostol suppositories alone. The need for analgesics in the group receiving Misoprostol 
suppositories and Hyoscine was significantly less than in the group receiving Misoprostol 
suppositories alone (p < 0.001). Finally, results of this study showed that adding 20 mg Hyoscine intra 
venous to vaginal Misoprostol is effective in significantly reducing the duration of the abortion 
induction, getting less pain killers, less vaginal bleeding and less decrease in hemoglobin changes.  
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INTRODUCTION 
 
Induced abortion is the termination of pregnancy by 
medical or surgical methods before the fetus’ viability 
(Cunningham et al., 2010). Induce abortion in pregnant 
women is done due to medical causes, social problems 
or fetal disorders. Currently, severe anatomical, meta-
bolic or rational abnormalities are the most common 
indications for induced abortion (Cunningham et al., 
2010). Failure of abortion induction in presence of  unripe  
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cervix may lead to surgical termination of pregnancy 
(Alfirevic et al., 2009); therefore, the use of prosta-
glandins was considered to be helpful for cervical 
ripening. E1 and E2 prostaglandins are usable for cervical 
maturation. Type E1 (Misoprostol) is more clinical 
applicable (Cunningham et al., 2010). 
Side effects of prostaglandins (nausea and vomiting, 
diarrhea and fever) are an obstructive element of their 
use (Cunningham et al., 2010). Available evidences show 
that due to spasmolytic effects, use of Hyoscine with 
Misoprostol may reduce the pain during abortion 
induction (Baracho and Kamat, 1982; Tehranian, 2010). 
Hyoscine with Misoprostol  may  also  reduce  duration of  
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Table 1. Comparing demographic characteristics of patients between two 
groups. 
 
Parameter 
Group 
P 
Case Control 
Age  25.97±5.95 25.67±5.26 0.99 
    
Gravidity 
1 15 (23.4%) 8 (12.7%) 
0.283 
2 20 (31.3%) 18 (28.6%) 
3 14 (21.9%) 24 (38.1%) 
4 12 (18.8%) 10 (15.9%) 
5 3 (4.7%) 3 (4.8%) 
     
Abortion frequency 
0 39 (60.9%) 38 (60.3%) 
0.893 1 23 (35.9%) 22 (34.9%) 
2 2 (3.1%) 3 (4.8%) 
     
Parity 
0 21 (33.3%) 11 (17.5%) 
0.124 
1 25 (39.7%) 29 (46%) 
2 9 (14.3%) 18 (28.6%) 
3 7 (11.1%) 4 (6.3%) 
4 1 (1.6%) 1 (1.6%) 
     
Gestational age (day) 69.69±14.94 71.05±9.46 0.541 
 
 
 
abortion induction due to increased cervical dilatation 
(Baracho and Kamat, 1982; Tehranian, 2010). According 
to prior studies, due to its spasmolytic effect and 
effectiveness on cervical dilatation, Hyoscine was 
effective in reducing the active labor duration (Sirohiwal 
et al., 2005; Samuels et al., 2007). Use of Hyoscine with 
doses up to 30 mg, has no significant side effects 
(Corsen, 1983). The aim of this study was to evaluate the 
effect of Misoprostol in combination with Hyoscine, 
compared with Misoprostol alone in reducing the duration 
of abortion induction. 
 
 
MATERIALS AND METHODS 
 
In a clinical trial at the Department of Obstetrics and Gynecology, 
Qazvin University of Medical Sciences on 126 pregnant women with 
gestational age below 20 weeks elected for abortion, the effect of 
Misoprostol in combination with Hyoscine, compared with 
Misoprostol alone, was evaluated in reducing the duration of 
abortion induction. A total of 126 pregnant women with gestational 
age below 20 weeks elected for abortion due to maternal or fetal 
problems were selected according to the inclusion/exclusion 
criteria, and randomized into two groups. Inclusion criteria included 
null pregnancy, forgotten abortion, and fetal malformations, and 
exclusion criteria were severe anemia, coagulopathy, use of 
anticoagulant drugs, active hepatic disease, cardiovascular 
disease, uncontrolled convulsion, history of adrenal disease and 
having intrauterine device (IUD), and history of mother’s allergy to 
prostaglandin and Hyoscine. 
After obtaining patients’ consent, they were randomly divided into 
two groups. The first group underwent vaginal Misoprostol regimen 
(400 mg/6 h) with 20 mg IV Hyoscine single dose, with the first dose 
of Misoprostol, and the second group got vaginal Misoprostol 
regimen (400 mg/6 h) with 1 cc IV normal saline. Patients were 
hospitalized and their vital signs were assessed every four hours. 
Patients’ symptoms including nausea, vomiting, fever, and vaginal 
bleeding was recorded. Vaginal examination was performed at the 
time of putting the first suppository, followed by vaginal bleeding.  
 
 
RESULTS 
 
In this study, there was no significant difference in 
demographic characteristics, including maternal age, 
gestational age, gravidity, parity and history of abortion 
between the two study groups, and the two groups were 
homogeneous. These parameters are shown in Table 1. 
Comparison duration of abortion induction and admitting 
duration between two groups are shown in Table 2. Side 
effects of treatment between two groups are shown in 
Table 3. Duration of abortion induction (p < 0.001) (Figure 
1), the rate of vaginal bleeding (p < 0.001), and the rate 
of hemoglobin deficiency (p = 0.002) in the group 
receiving Misoprostol suppositories and Hyoscine was 
significantly lower than in the group receiving Misoprostol 
suppositories alone. The need for analgesics in the group 
receiving Misoprostol suppositories and Hyoscine was 
significantly less than in the group receiving Misoprostol 
suppositories alone (p < 0.001). 
 
 
DISCUSSION 
 
The  results  of this study show that in the group receiving 
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Table 2. Comparing duration of abortion induction and admitting duration between two 
groups. 
 
Parameter 
Group 
P 
Case Control 
Duration of abortion induction (minute) 653.38±80.38 726.29±64.56 ≤0.001 
admitting duration (day) 103±0.17 1.02±0.12 1 
 
 
 
Table 3. Side effects of treatment between two groups. 
 
Parameter 
Group 
P 
Case Control 
Nausea 11 (17.2%) 9 (14.3%) 0.808 
Need to narcotic 8 (12.7%) 32 (50.8%) ≤0.001 
  
   
Vaginal bleeding 
(Sanitary napkin count) 
1 31 (48.4%) 2 (302%) 
≤0.001 2 29 (45.3%) 53 (84.1%) 
3 4 (6.3%) 8 (12.7%) 
    
   
Hemoglobin change 0.4391±0.23612 0.5597±0.24858 0.002 
 
 
 
9
5
%
 C
o
n
fi
d
e
n
c
e
 i
n
te
rv
a
l 
(C
I)
 t
im
e
 
 
 
 
 
 
 
Figure 1. Distribution of abortion induction time between two groups 
 
 
 
Misoprostol suppositories and Hyoscine, the mean 
duration of abortion induction was significantly shorter 
than in the group receiving Misoprostol suppositories 
alone   (653.38   ±   80.38   versus   726.29  ±  64.56 min)  
(p ≤ 0.001). Hyoscine is a muscarinic antagonist drug that 
causes loss of cervical spasm (Bhattacharya and Joshi, 
1985), and may help cervical dilatation affecting uterine 
cervical neural system (Baracho and Kamat, 1982). 
 
 
 
 
Vagal stimulation leads to increased spasms in the lower 
uterine segment and the cervix, and Hyoscine, as a kind 
of parasympatholytic drug, helps cervical dilatation 
affecting the vagus (Baracho and Kamat, 1982). Thus, 
regarding the effects of Hyoscine on the cervix, it may 
reduce the duration of abortion induction in the group 
receiving Hyoscine. 
Tewari et al. (2003) demonstrated that administration of 
40 mg IV Hyoscine in two divided doses reduced the 
mean duration of labor by five hours and twelve minutes 
in the group receiving hyoscine compared with the control 
group. Battacharya et al. (1985) studied the effect of 20 
mg IM Hyoscine in the active phase of labor in 10 prim 
gravid women and concluded that the mean duration of 
labor is reduced by three hours and 40 minutes. In a 
study by Samel et al. (1998) and Samuels et al. (2007), 
IV administration of 20 mg Hyoscine had also led to 
shorter duration of labor.  
In our study, as well as the results of these studies, 
administration of Hyoscine led to reduced duration of 
induction abortion in patients under study. In terms of the 
need for analgesics, the intervention group than the 
control group had significantly less need for analgesics 
(12.7 versus 50.8%) (p ≤ 0.001). In the study by 
Tehranian (2010), pain score was lower in the 
intervention group than in the control group, but this 
difference was not statistically significant. 
Aggarwal et al. (2008) demonstrated that IV Hyoscine 
relieves the pain by 36% during labor. Perhaps one of the 
reasons for differences among studies is the severity of 
the pain that patients can tolerate, and the pain threshold 
varies in different individuals. In our study, rate of nausea 
and vomiting in the intervention group was lower than in 
the control group, but this difference was not statistically 
significant. The rate of vaginal bleeding in terms of the 
number of sanitary pads used in our intervention group 
was significantly lower than in the control group (p ≤ 
0.001) and no fever and diarrhea were observed in any 
patient. Mean hemoglobin changes before and 6 h after 
labor were 0.4391 ± 0.23 in the intervention group and 
0.5597 ± 0.24 in the control group; that in the intervention 
group was significantly lower than in the control group (p 
= 0.002) 
 
 
Conclusion 
 
Results of this study showed that compared with vaginal 
Misoprostol, IV administration of 20 mg Hyoscine with 
400 µg vaginal Misoprostol significantly reduces duration 
of abortion induction, the need for analgesics, vaginal 
bleeding and drop in blood hemoglobin levels. Therefore, 
further studies are recommended to be conducted with 
larger sample size to investigate this efficiency. 
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